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DEAR EDITOR, Skin diseases affect a significant percentage of the
population and are often the result of a complex interplay
between autoimmune dysregulation, and abnormal epidermal
differentiation and proliferation. Origins may be genetic and/
or environmental, and while no complete cure exists for con-
ditions such as psoriasis, a range of treatments, including reti-
noids and antibodies against tumour necrosis factor-a and
interleukin-17, have shown therapeutic efficacy, although
relapses can occur.1 While there is no definitive mouse model
for psoriasis, some do present with abnormal skin phenotypes
that have revealed interesting molecular drivers.1 For example,
agonist-treated peroxisome proliferator-activated receptor
(PPAR) b/d transgenic mice develop psoriasis-like conditions
with failed compaction of the granular layer, which can be
countered by PPARb/d antagonists.2 PPARb/d is also upregu-
lated in human psoriasis and murine ichthyosis,2,3 but has
proinflammatory, anti-inflammatory and prodifferentiation
properties in various contexts.4,5 PPARc, although predomi-
nantly expressed in the sebaceous gland, has similar prodiffer-
entiation effects, and can reduce inflammation and promote
barrier formation in mice with induced parakeratosis (Fig. S1;
see Supporting Information).6
The tumour suppressor p53 is upregulated in the pathogen-
esis of human chronic plaque-type psoriasis (Fig. 1a), and its
role in skin disease has long been questioned.7 In additional
animal studies, p53 has been found to be largely dispensable
to epidermal homeostasis, with gene loss only causing minor
alterations in murine catagen,8 and paradoxically, p53 deletion
reduces oncogenesis in transgenic mouse skin carcinogenesis
studies.9 p53 knockdown also promotes squamous differentia-
tion in human keratinocytes cultured in vitro,10 which suggests
p53 activation may impair keratinocyte differentiation in the
interfollicular epidermis; however, this has not been tested
in vivo.
A parakeratotic differentiation programme can be invoked
by high MYC activity in keratinocytes; thus, K14MycER mice
form a useful model of hyperproliferative skin. They overex-
press MYC fused with the tamoxifen-responsive mutant
oestrogen receptor ligand binding domain in the keratin 14
(K14)-positive basal layer of the epidermis and, upon activa-
tion with high-dose 4-hydroxytamoxifen (4OHT), exhibit
parakeratotic lesions of acanthosis, hyperkeratosis and dermal
inflammatory infiltration (see Fig. S1; see Supporting Informa-
tion).11,12 Our K14MycER mice also show dose-dependent acti-
vation of the tumour suppressor p53 (Fig. 1b).13
We previously crossed K14MycER mice with p53 knockout
animals and demonstrated that aberrant p53 activity interferes
with sebaceous gland differentiation by impairing androgen
receptor function.13 In this study we investigated if p53
activity also contributes to defective interfollicular epidermal
differentiation in the same cohort of animals. Full materials
and methods are available in Appendix S1 (see Supporting
Information). Our results show K14MycER p53null mice exhib-
ited persistent hyperproliferation (Fig. S1; see Supporting
Fig 1. Characterization of K14MycER p53null mouse epidermis. (a) Human scalp and psoriasis lesions immunostained for p53 (n = 6). (b) Mouse
back skin from wild-type (WT:), K14MycER (Myc:) and K14MycER p53 knockout (Myc: p53null) mice 4 days after treatment with 01 mg or
15 mg 4-hydroxytamoxifen as indicated, immunostained for p53 and counterstained with haematoxylin. (c) Mice treated as in (b), including
p53 knockout (p53null) controls stained with haematoxylin and eosin (H&E). The granular layer was not visible in 2139  001% of K14MycER
p53 wild-type (WT; p53wt) skin (as a proportion of length) and 2264  003% of K14MycER p53 heterozygous (p53het) skin. In contrast, the
granular layer was only absent in 1085  003% of K14MycER p53null skin (*P < 005). (d) Mouse skin immunostained for keratin 6 (K6) and
keratin 14 (K14), and counterstained with nuclear dye 40,6-diamidino-2-phenylindole (DAPI); (e) mouse skin immunostained for K14, fatty acid
binding protein 5 (FABP5) and DAPI; and (f) mouse skin immunostained for K14, loricrin (LOR) and DAPI. (g–n) Quantitative reverse
transcription polymerase chain reaction for indicated mRNAs relative to Gapdh, standardized to WT mice (defined as 1). K14MycER (Myc:) mice
shown by grey bars of p53wt, p53het and p53null status. (j) MYC activity alone induced downregulation of Krt10 mRNA, although (k) the K10
protein persists in this time frame and there is upregulation of Flg mRNA (Fig. S1; see Supporting Information). (l, m) Genes that showed MYC
and p53-dependent regulation included Ivl and Ppl, such that deletion of even one functional p53 allele resulted in a significant upregulation of
mRNA. (g, n) Most significantly, hyperproliferative Krt6a and Pparb/d expression, which was upregulated in K14MycER p53wt/het mice, was reduced
in K14MycER p53null mice. We have shown previously that K14MycER p53null mice have increased Pparg mRNA expression,13 and here demonstrate the
increased peroxisome proliferator-activated receptor (PPAR) c protein expression is predominantly in the sebaceous gland (Fig. S1; see Supporting
Information). n = 3–5. Error bars represent SEM. #P < 006; *P < 005, **P < 001, ***P < 0005. Scale bars 50 lm. Rel. Exp., relative
expression.
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Information),13 skin thickening and K14-positive basal layer
expansion (Fig. 1c, d); however, deletion of p53 causes a
number of positive changes, with reduced keratin 6 (K6)
expression (Fig. 1d, g), partial redistribution of the ker-
atinocyte differentiation marker fatty acid binding protein 5
(FABP5) towards terminal differentiating layers (Fig. 1e, h),
and improved granular layer compaction (Fig. 1). Additional
quantitative reverse-transcription polymerase chain reaction
(qRT-PCR) analysis showed that MYC activity reduced Krt10
mRNA expression (Fig. 1j), although keratin 10 (K10) protein
persisted in the uppermost keratinocyte layers (Fig. S1; see
Supporting Information). MYC activity also promoted the
expression of Flg and Ivl but these (and K10) did not change
further upon deletion of p53 (Fig. 1j–m). However, loss of
p53 reduced Krt6a (Fig. 1g), upregulated Pparg and normalized
mRNA expression of Pparb/d [Fig. 1n; Fig. S1 (see Supporting
Information)].13
Retinoic acid (RA) signalling is important to skin biology
yet there is no previous evidence for cross-talk between p53
and RA signalling in skin. A recent study has demonstrated
that p21(RAC)-activated kinase 2 (PAK2)-phosphorylated MYC
binds and co-activates RA receptor (RAR) a, while unphos-
phorylated MYC acts as a co-repressor.14 As we observed non-
apoptotic p53 activation in response to MYC, we set out to
examine if this was related to RAR signalling by using
the reverse agonist BMS493 to promote stabilization of
RAR/retinoid X receptor repressive complexes.15 This drug
promoted granular formation and prevented the induction of
p53 (Fig. 2a, b). We had also previously generated K14MycAER
mice, possessing three MYC point mutations to prevent PAK2
phosphorylation, and predicted ‘MYCA’ would therefore
mimic BMS493 to function as a RAR co-repressor. Our predic-
tion proved true, as K14MycAER mice did, indeed, retain granu-
lar formation (Fig. 2c), and showed markedly reduced p53
expression and p53 activation (Fig. 2d, e). As in K14MycER
mice, hyperproliferation, skin thickening and basal layer
expansion still occurred [Fig. 2c, f; Fig. S1 (see Supporting
Information)], and Krt10 mRNA expression was also reduced,
while the K10 protein persisted [Fig. 2i; Fig. S1 (see Support-
ing Information)]. However, points of difference included that
K6 was not as greatly upregulated and FABP5 was predomi-
nantly observed in upper differentiating keratinocytes in
K14MycAER mice (Fig. 2f, g). Loricrin was also more com-
pacted (Fig. 2h). Further qRT-PCR analysis of K14MycAER mice
confirmed reduced Krt6a expression (Fig. 2j), along with
upregulation of Pparg and normalized Pparb/d mRNA expression
(Fig. 2k, l). Thus, K14MycAER mice phenocopy K14MycER
p53null mice (Fig. 2m). Of further interest, in contrast to
K14MycER mice, K14MycAER mice also maintained their granular
layer when challenged with the strongly p53-activating com-
pound, camptothecin (Fig. S1; see Supporting Information),
suggesting PAK2 unphosphorylated MYC is the form of MYC
that counteracts p53.
A question that arises is how p53 activity predominantly
detected in basal cells can trigger such changes in differentiat-
ing keratinocytes. One possibility is that p53 promotes basal
keratinocyte-secreted inflammatory mediators that influence
differentiating cells. In line with this general idea, we recently
showed how chemokine upregulation increases disease sever-
ity by impairing keratinocyte terminal differentiation in a
mouse model of harlequin ichthyosis.3
In conclusion, we identified that p53 signalling reduces
Pparg and promotes Pparb/d and Krt6a expression. This has phys-
iological significance as it controls granular layer formation
(Fig. 2n). We also highlight for the first time, the significant
convergence of the p53 and RAR signalling pathways via MYC
and demonstrate that repression of RARs can inhibit p53 activ-
ity to restore granular layer formation, which is presumably
good for barrier function. Given p53 is an integrator of multi-
ple stress responses, these findings may provide mechanistic
insight into the pathogenesis of human skin diseases where
granular formation is disrupted.
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Fig 2. Retinoic acid signalling and p53. (a) Mouse telogen back skin [wild-type (WT:) and K14MycER (Myc:) mice] treated once with acetone or
15 mg 4-hydroxytamoxifen (4OHT) and daily with 0016 mg BMS493 for 4 days, stained with haematoxylin and eosin (H&E) and (b)
immunostained for p53 with haematoxylin counterstain. (c) Haematoxylin and eosin analysis of K14MycAER (MycA:) mice treated with 15 mg
4OHT after 4 days. (d) p53 immunostaining of mice in (c) with haematoxylin counterstain. (e) Quantitative reverse transcription polymerase
chain reaction (qRT-PCR) for p53 mRNA relative to Gapdh, standardized to wild-type (WT) mice (defined as 1). Mice (including transgenics and
WT siblings) from the K14MycER (Myc:) strain are shown by white bars and mice from the K14MycAER (MycA:) strains are shown by the grey
bars. (f) Immunostained for keratin 6 (K6), keratin 14 (K14) and 40,6-diamidino-2-phenylindole (DAPI), (g) immunostained for K14, fatty acid
binding protein 5 (FABP5) and DAPI, and (h) immunostained for K14, loricrin (LOR) and DAPI. (i–l) qRT-PCR for indicated mRNAs relative to
Gapdh, standardized to WT mice (defined as 1). Mice (including transgenics and WT siblings) from the K14MycER (Myc:) strain are shown by
white bars and mice from the K14MycAER (MycA:) strains are shown by the grey bars. (m) Summary of gene changes in transgenic mouse strains.
(+) indicates gain, () indicates reduction, (o) indicates unchanged. Magnitude indicated by number of  symbols. (o) Summary model of
proposed signalling pathway (note that BMS493 and MYCA can inhibit retinoic acid receptor activity and prevent p53 activity). n = 3–9. Error
bars represent SEM. #P < 006, *P < 005, ***P < 0005, **P < 001. Scale bars = 50 lm. N/A, not applicable; Rel. Exp., relative expression;
PPAR, peroxisome proliferator-activated receptor.
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Supporting Information
Additional Supporting Information may be found in the online
version of this article at the publisher’s website:
Appendix S1. Materials and methods.
Fig S1. Further characterization of K14MycER, K14MycER
p53null and K14MycAER mouse epidermis.
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